Columbus, OH (PRWEB) April 27, 2012
EndoSphere Inc. today announced that it received CE Mark regulatory approval for the Satisphere™ System, a noninvasive device for the treatment for obesity – one of the world’s largest health issues. The Satisphere device improves regulation of appetite and satiety by using the body’s natural physiology. The endoscopically-insertable device is completely incisionless, reversible, and repeatable.
Worldwide obesity rates have become staggering. According to the Centers for Disease Control (CDC), obesity rates increased so dramatically during the past decade that today, more than 35% of U.S. adults nationwide suffer from obesity. In 2000, not a single U.S. state had an obesity rate above 30%. Annual costs attributed to obesity and its co-morbidities are currently estimated at $147 billion and rising.
Clinical studies have shown that the Satisphere device enables obese patients to achieve significant weight loss without surgery or medication. The granting of CE (European Conformity) Mark indicates that the Satisphere device has been carefully reviewed and found to be compliant with the requirements of European health, safety and environmental protection regulations. The CE Mark provides government approval for the Satisphere device to be legally placed on the market in 31 countries including all countries within the European Economic Area (EEA) and additional countries within the European Free Trade Association (EFTA).
“The granting of regulatory approval for the Satisphere device opens doors for those suffering from obesity to gain access to this promising new treatment,” said Christopher Thorne of Broadline Capital, who serves as EndoSphere's executive chairman. “Our team is inspired by the potential for EndoSphere’s medical technologies to help millions of people who suffer from obesity, type 2 diabetes and other serious metabolic diseases.”
About EndoSphere Inc.
Founded in 2006, EndoSphere Inc. is a pioneer of endoscopically-insertable medical technologies for the betterment of humankind. The company holds a portfolio of 25 issued and pending U.S. and international patents. Its flagship product, the Satisphere™ System, is a noninvasive treatment for one of the world’s largest health issues: obesity and its co-morbidities. EndoSphere is a portfolio company of Broadline Capital, a global private equity investment firm, and major co-investors include Ohio TechAngel Funds II and III, Co-Investment Fund, Glengary, North Coast Angel Fund II, Physician Investment Group, and QCA First Fund III. For more information, please visit http://www.EndoSphereInc.com.